NRx Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NRXP | TNXP | NMRA | VNDA | AVXL | MPLT | |
|---|---|---|---|---|---|---|
| Market cap | 107.81M | 87.64M | 106.35M | 234.62M | 116.80M | 372.91M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -7.1 | -0.7 | -0.9 | 19.4 | -2.3 | -2.0 |
| Price/book | -622.5 | 0.4 | 2.4 | 1.2 | 1.0 | 0.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −6.74% | −71.36% | −78.21% | −15.54% | −83.58% | −58.43% |
| Today | +11.16% | −1.54% | −0.86% | +3.47% | +5.00% | −1.47% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All NRXP news ›NRIX Slumps 35% After-Hours — What’s Driving The Selloff?
Shares of Nurix Therapeutics, Inc. (NRIX) slumped 35% after hours on Tuesday after the company said that its partner Sanofi (SNY) has discontinued development of the experimental oral drug called SAR448272 that it licensed from Nurix.…
FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
PRLog FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals,
NRXP Slides As NRX Pharmaceuticals Inc. Faces Deep Losses
NRX Pharmaceuticals Inc. stocks have been trading down by -16.92 percent after news highlighting intensified operational and financing risks. Market Insights For Active NRXP Traders Price has fallen from a recent push above $3.60 to around…
NRXP Slides As Traders React To Weak Financial Profile
NRX Pharmaceuticals Inc. faces heightened investor anxiety after adverse trial news, with stocks having been trading down by -16.92 percent Market Insights For Active NRXP Traders Weekly chart shows NRXP running from the $2.50 area to a…
NRXP Stock Dips As Traders Weigh Steep Losses And Cash Runway
NRX Pharmaceuticals Inc. faces heightened pressure as critical clinical trial delays emerge, while stocks have been trading down by -16.92 percent. What Traders Need To Know Weekly chart shows NRXP swinging between $2.21 and $3.62, with…
NRx Clears Manufacturing Hurdle for Ketamine FDA Review
WILMINGTON, DE — NRx Pharmaceuticals Inc. (Nasdaq: NRXP) has completed commercial-scale manufacturing validation for its preservative-free injectable ketamine, positioning the company to begin supplying U.S. hospitals and clinics if the…
NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA Approval of Preservative-Free Ketamine Transcript
NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA Approval of Preservative-Free Ketamine October 30, 2026 8:30 AM EDT Jonathan Javitt - Co-Founder, Chairman & CEO Brian KorbElemer Piros - Lucid Capital Markets, LLC, Research DivisionPatrick…
NRx Pharma rises on FDA nod for generic ketamine injection
NRx Pharmaceuticals (NRXP) stock gains as the FDA approves its generic ketamine injection, potentially easing supply constraints for therapy. Read more here. - NRx Pharmaceuticals (NRXP) added more than 15% in premarket trading on Friday…
Psychedelic: NRx Pharmaceuticals receives FDA labeling review letter
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a FDA request, a scientific ad... Psychedelic: NRx Pharmaceuticals receives FDA labeling review letter In this week’s…
NRx Pharmaceuticals Receives FDA Label Revision Request For Its Preservative-Free Ketamine Product
Thursday, NRx Pharmaceuticals, Inc. (NRXP) announced that the U.S. Food and Drug Administration has requested minor changes to the submitted label for NRx's Preservative-Free Ketamine product. NRx Pharmaceuticals Receives FDA Label…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- stocktitan.net4
- seekingalpha.com2
- stockstotrade.com2
- globenewswire.com1
- markets.businessinsider.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 16 articles, not a forecast.